Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma

Trial Profile

Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 May 2017

At a glance

  • Drugs Abiraterone acetate (Primary)
  • Indications Adrenocortical carcinoma; Cushing syndrome
  • Focus Therapeutic Use
  • Acronyms ABACUS
  • Most Recent Events

    • 11 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top